The MDA-MB-231 cell line is derived from triple-negative breast cancer (TNBC), representing one of the most aggressive forms of breast cancer. Innovative therapeutic strategies, including s targeted therapies using nanocarriers, hold significant promise, particularly for difficult-to-treat cancers such as TNBC. Nanoparticles have transformed the medical field by serving as advanced drug delivery systems for cancer treatment. They play a critical role in overcoming the drug resistance often associated with cancer therapies. When utilized as drug delivery vehicles, nanoparticles can specifically target cancer cells and effectively reduce or eliminate multidrug resistance. Among them, chitosan-coated magnetic nanoparticles (MNPs) have been widely explored for the loading and controlled release of various anticancer agents. In this study, we evaluated the effects of dexamethasone-loaded chitosan-coated MNPs on MDA-MB-231 cell lines. Fourier transform infrared spectroscopy and scanning electron microscopy were employed to verify the successful loading of dexamethasone onto the nanoparticles. To assess cytotoxicity, empty nanoparticles, free drug, and drug-loaded nanoparticles were tested on the cells. The results indicated that empty nanoparticles exhibited no toxic effects. The IC50 value of the free drug was 123 µg/mL, while the IC50 value of the drug-loaded nanoparticles was significantly lower, at 63 µg/mL. These findings confirmed the successful conjugation of dexamethasone to the chitosan-coated MNPs, demonstrating substantial cytotoxic effects on breast cancer cells. Although dexamethasone has been reported to exhibit both tumor-suppressive and pro-metastatic effects, its specific impact on TNBC warrants further investigation in future studies.

nanoparticles; dexamethasone; breast cancer; cytotoxicity

1. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nature Reviews Disease Primers. 2019; 5(1). doi: 10.1038/s41572-019-0111-2

2. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134-1150. doi:10.1016/S0140-6736(16)31891-8

3. Hong R, Xu B. Breast cancer: an up‐to‐date review and future perspectives. Cancer Communications. 2022; 42(10): 913-936. doi: 10.1002/cac2.12358

4. Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases. 2018; 5(2): 77-106. doi: 10.1016/j.gendis.2018.05.001

5. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3

6. Akram M, Iqbal M, Daniyal M, et al. Awareness and current knowledge of breast cancer. Biological Research. 2017; 50(1). doi: 10.1186/s40659-017-0140-9

7. McDonald ES, Clark AS, Tchou J, et al. Clinical Diagnosis and Management of Breast Cancer. Journal of Nuclear Medicine. 2016; 57(Supplement 1): 9S-16S. doi: 10.2967/jnumed.115.157834

8. Huang Z, Yu P, Tang J. Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model OncoTargets and Therapy. 2020; 13: 5395-5405. doi: 10.2147/ott.s249756

9. Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers. 2022; 14(10): 2569. doi: 10.3390/cancers14102569

10. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Advances in Cancer Research. Published online 2018: 115-170. doi: 10.1016/bs.acr.2017.11.003

11. Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews. 2018; 130: 17-38. doi: 10.1016/j.addr.2018.07.007

12. Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Research Letters. 2021; 16(1). doi: 10.1186/s11671-021-03628-6

13. Yao Y, Zhou Y, Liu L, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Frontiers in Molecular Biosciences. 2020; 7. doi: 10.3389/fmolb.2020.00193

14. Zhu L, Ma J, Jia N, et al. Chitosan-coated magnetic nanoparticles as carriers of 5-Fluorouracil: Preparation, characterization and cytotoxicity studies. Colloids and Surfaces B: Biointerfaces. 2009; 68(1): 1-6. doi: 10.1016/j.colsurfb.2008.07.020

15. Parsian M, Unsoy G, Mutlu P, et al. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug. European Journal of Pharmacology. 2016; 784: 121-128. doi: 10.1016/j.ejphar.2016.05.016

16. Oh Y, Lee N, Kang HW, et al. In vitrostudy on apoptotic cell death by effective magnetic hyperthermia with chitosan-coated MnFe2O4. Nanotechnology. 2016; 27(11): 115101. doi: 10.1088/0957-4484/27/11/115101

17. Thorat ND, Otari SV, Patil RM, et al. Synthesis, characterization and biocompatibility of chitosan functionalized superparamagnetic nanoparticles for heat activated curing of cancer cells. Dalton Trans. 2014; 43(46): 17343-17351. doi: 10.1039/c4dt02293a

18. National Center for Biotechnology Information (NCBI). PubChem Compound Summary for CID 5743: Dexamethasone. Accessed January 24, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone

19. Dey KK, Ghosh M. Understanding the structure and dynamics of anti-inflammatory corticosteroid dexamethasone by solid state NMR spectroscopy. RSC Advances. 2020; 10(61): 37564-37575. doi: 10.1039/d0ra05474g

20. Unsoy G, Yalcin S, Khodadust R, et al. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. Journal of Nanoparticle Research. 2012; 14(11). doi: 10.1007/s11051-012-0964-8

21. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols. 2007; 2(2): 329-333. doi: 10.1038/nprot.2007.30

22. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers. J Control Release. 2001;70(3):399-421. doi:10.1016/S0168-3659(00)00361-8

23. Corsi K, Chellat F, Yahia L, Fernandes JC. Mesenchymal stem cell transfection using chitosan-DNA nanoparticles. Biomaterials. 2003;24(7):1255-1264. doi:10.1016/S0142-9612(02)00507-0

24. Baghdan E, Pinnapireddy SR, Strehlow B, et al. Lipid coated chitosan-DNA nanoparticles for enhanced gene delivery. International Journal of Pharmaceutics. 2018; 535(1-2): 473-479. doi: 10.1016/j.ijpharm.2017.11.045

25. Martin JD, Panagi M, Wang C, et al. Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment. ACS Nano. 2019; 13(6): 6396-6408. doi: 10.1021/acsnano.8b07865

26. Zhou L, Shen Y, Huang T, et al. The Prognostic Effect of Dexamethasone on Patients With Glioblastoma: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2021; 12. doi: 10.3389/fphar.2021.727707

27. Jessurun CAC, Hulsbergen AFC, Cho LD, et al. Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? Journal of Neuro-Oncology. 2019; 144(2): 249-264. doi: 10.1007/s11060-019-03238-4

28. Crozier M, Tubman J, Fifield BA, et al. Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells. Seagroves T, ed. PLOS ONE. 2022; 17(9): e0274675. doi: 10.1371/journal.pone.0274675

29. Zhang X, et al. Dexamethasone promotes metastasis in ER-negative breast cancer via EMT. J Exp Clin Cancer Res. 2021;40(1):64. doi:10.1186/s13046-021-01859-1

30. Yalçın S, Erkan M, Ünsoy G, et al. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomedicine & Pharmacotherapy. 2014; 68(6): 737-743. doi: 10.1016/j.biopha.2014.07.003